Get the Stockscreener App
23.46
4.97%
1.11
After Hours:
23.39
-0.07
-0.30%
Sarepta Therapeutics Inc stock is traded at $23.46, with a volume of 3.28M.
It is up +4.97% in the last 24 hours and up +5.39% over the past month.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
See More
Previous Close:
$22.35
Open:
$22.5
24h Volume:
3.28M
Relative Volume:
0.75
Market Cap:
$2.46B
Revenue:
$2.48B
Net Income/Loss:
$-57.96M
P/E Ratio:
-30.93
EPS:
-0.7585
Net Cash Flow:
$-453.97M
1W Performance:
+9.01%
1M Performance:
+5.39%
6M Performance:
+35.45%
1Y Performance:
-81.16%
1-Day Range:
$22.17
$24.10
1-Week Range:
$20.86
$24.10
52-Week Range:
$10.41
$128.75
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
23.46 | 2.34B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Wedbush | Outperform |
| Nov-05-25 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-22-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-29-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-25 | Initiated | Bernstein | Mkt Perform |
| Jul-29-25 | Reiterated | H.C. Wainwright | Sell |
| Jul-29-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Jul-29-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-28-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Jul-25-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-25 | Initiated | Citigroup | Sell |
| Jul-23-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-22-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-21-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-21-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jul-21-25 | Downgrade | Needham | Hold → Underperform |
| Jul-21-25 | Downgrade | UBS | Buy → Neutral |
| Jul-18-25 | Downgrade | Needham | Buy → Hold |
| Jun-20-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-25 | Downgrade | TD Cowen | Buy → Hold |
| Jun-17-25 | Initiated | Wolfe Research | Peer Perform |
| Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
| Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigat - pharmiweb.com
Sarepta submits clinical trial application for Huntington’s disease drug By Investing.com - Investing.com India
Sarepta (SRPT) Moves Forward with New Clinical Trial Application for Huntington's Treatment - GuruFocus
Sarepta submits clinical trial application for Huntington's disease drug - StreetInsider
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease - Yahoo Finance
Why analysts raise outlook for Sarepta Therapeutics Inc. (AB3A) stock2026 world cup usa national team round of 32 star players high defensive line expert forecast preview - Улправда
Standing by Our Decision: How EXONDYS 51 Became Part of Our Treatment Plan - Muscular Dystrophy News
Buybacks Report: What risks investors should watch in Sarepta Therapeutics Inc stockBreakout Watch & Intraday High Probability Setup Alerts - moha.gov.vn
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - New Castle News
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: A Biotech Pioneer with a Mixed Valuation Outlook - DirectorsTalk Interviews
Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Cwm LLC - MarketBeat
United States Neuromuscular Disease Therapeutics Market - openPR.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 31, 2025 - BioSpace
Sarepta Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals
Voya Investment Management LLC Trims Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Reach - openPR.com
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny - MSN
Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 - openPR.com
Japan Gene Therapy Market is expected to reach US$ 904.94 Million - openPR.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys - MSN
Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com
Assenagon Asset Management S.A. Sells 838,457 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Pauses Shipments Of DMD Drug Elevidys Amid FDA Label Review, Stock Tumbles After-Hours - MSN
Sarepta Therapeutics Earnings Notes - Trefis
Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Tuesday? (CORRECTED) - Benzinga
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 3.5%Here's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Sarepta to refinance $291M of existing notes due 2027 - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Reach Out - ACCESS Newswire
Aug Intraday: Will Sarepta Therapeutics Inc stock split attract more investorsOil Prices & Verified Momentum Stock Watchlist - moha.gov.vn
Have Insiders Sold Sarepta Therapeutics Shares Recently? - simplywall.st
How Sarepta Therapeutics Inc. stock compares to industry benchmarksPortfolio Gains Report & Real-Time Market Trend Scan - ulpravda.ru
Sarepta Therapeutics exchanges $291.4 million in convertible notes for new securities By Investing.com - Investing.com Nigeria
Sarepta Therapeutics Extends Debt Maturities with New Notes - TipRanks
Sarepta Therapeutics exchanges $291.4 million in convertible notes for new securities - Investing.com
Sarepta Therapeutics Signs Multiple Financing Agreements - TradingView — Track All Markets
What Does the Market Think About Sarepta Therapeutics Inc? - Benzinga
Is Sarepta Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Patterns & Reliable Price Action Trade Plans - DonanımHaber
Sarepta Therapeutics (NASDAQ:SRPT) COO Ian Michael Estepan Sells 13,187 Shares - MarketBeat
Insider Sale: Chief Operating Officer of $SRPT Sells 13,187 Shares - Quiver Quantitative
Sarepta Therapeutics COO Sells Shares - TradingView — Track All Markets
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect - ACCESS Newswire
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Finviz
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Yahoo Finance
Will FDA Liver Warning and Newborn Screening Expansion Change Sarepta Therapeutics' (SRPT) Risk‑Reward Narrative? - Sahm
Will Sarepta Therapeutics Inc. stock maintain momentum in 2025Exit Point & Technical Buy Zone Confirmations - Улправда
Sarepta Therapeutics Inc Stock Analysis and ForecastRisk-Reward Ratio Analysis & Low Entry Investment Portfolio - earlytimes.in
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - Stock Traders Daily
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):